病原体减少血小板在儿童体外循环手术中的止血效果评估
该回顾性研究纳入2020至2022年体外循环术后心脏重症监护病房患儿522例,比较接受病原体减少血小板与大规模延迟采样血小板者的止血效果。结果显示两组术后24小时内胸管引流量及红细胞、血浆等输血量均无显著差异,提示病原体减少血小板可提供足够止血效果。
要点
- 病原体减少血小板与LVDS血小板在儿童体外循环术后24小时胸管引流量无显著差异。
- 两组在红细胞、血浆、冷沉淀及细胞回收输血量上均无显著差异。
- 病原体减少血小板在该人群中止血效果充分,且理论上可降低微生物污染风险。
核心结论
- 儿童体外循环术后接受病原体减少血小板者胸管引流量与LVDS血小板相当,且未增加输血需求。
研究设计与样本
- 回顾性研究,纳入2020至2022年体外循环术后心脏重症监护病房患儿522例,其中47%(243/522)接受LVDS血小板,53%(279/522)接受病原体减少血小板。
临床怎么用
- 儿童体外循环手术中可考虑使用病原体减少血小板作为LVDS血小板的替代,止血效果相当且可能降低微生物污染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children undergoing cardiopulmonary bypass (CPB) surgery are vulnerable to bleeding and often require transfusions. Pathogen-reduced (PR) platelets may reduce microbial contamination but are associated with decreased platelet count increments and increased transfusions. We sought to evaluate hemostasis in children undergoing CPB surgery receiving PR platelets vs large-volume delayed sampling (LVDS) platelets. METHODS: We performed a retrospective review of children in a cardiac intensive care unit after CPB surgery from 2020 to 2022. Demographics, operative characteristics, transfusion details, and outcomes were compared. The primary outcome was postoperative chest tube bleeding in the first 24 hours. RESULTS: There were 522 patients enrolled; 47% (243/522) received LVDS platelets and 53% (279/522) received PR platelets. Median (interquartile range) age was 4 (0-29) months. There were no differences in age (P = .499) or The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery congenital heart surgery mortality score (P = .813). There were no differences between platelet groups in postoperative chest tube bleeding at 1 hour (2.9 vs 3.2 mL/kg; P = .179), 2 hours (4.9 vs 5.1 mL/kg; P = .368), 4 hours (7.7 vs 8.1 mL/kg; P = .433), 8 hours (11.9 vs 12.9 mL/kg; P = .610), 12 hours (17.0 vs 17.1 mL/kg; P = .966), or 24 hours (28.0 vs 27.0 mL/kg; P = .536) after surgery. There were also no differences in doses of red blood cells (P = .054), cell salvage (P = .220), plasma (P = .337), or cryoprecipitate (P = .091). CONCLUSIONS: Children who received PR platelets had the same amount of chest tube output and did not require increased transfusions compared with LVDS platelet recipients. In children undergoing CPB surgery, PR platelets appeared to provide adequate hemostasis with further theoretical benefit of reduced microbial contamination.
引用
- Hsien S, Reinert S, Shamash J, et al. Assessing the Efficacy of Pathogen-Reduced Platelet Transfusions for Hemostasis in Children Undergoing Cardiopulmonary Bypass Surgery. Ann Thorac Surg. 2025. PMID: 40653045. doi:10.1016/j.athoracsur.2025.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。